Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology
Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …
Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
MP Yadav, S Ballal, RK Sahoo, SN Dwivedi… - American Journal of …, 2019 - ajronline.org
OBJECTIVE. Several clinical studies have shown the efficacy of 177Lu-labeled prostate-
specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration …
specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration …
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, R Baum… - European journal of …, 2019 - Springer
Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
be identified by PSMA-ligand imaging, which has already become clinically accepted in …
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
FE von Eyben, G Roviello, T Kiljunen… - European journal of …, 2018 - Springer
Aims There is a controversy as to the relative efficacy of 177 Lu prostate specific membrane
antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with …
antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with …
Results of a prospective phase 2 pilot trial of 177Lu–PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment …
Abstract Background 177 Lu–PSMA-617 (Lu-PSMA) is an emerging therapy in men with
metastatic castration-resistant prostate cancer. Paired theranostic agents have the potential …
metastatic castration-resistant prostate cancer. Paired theranostic agents have the potential …
PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy
Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation
in the past two decades as a promising molecular target for prostate cancer (PCa). Its …
in the past two decades as a promising molecular target for prostate cancer (PCa). Its …
A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177–labeled prostate-specific membrane antigen–targeted radioligand therapy in …
Context Castration-resistant prostate cancer (CRPC) treatment is an evolving challenge.
Prostate-specific membrane antigen (PSMA)-targeted endoradiotherapy/radioligand therapy …
Prostate-specific membrane antigen (PSMA)-targeted endoradiotherapy/radioligand therapy …
[HTML][HTML] Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer
NP Lenzo, D Meyrick, JH Turner - Diagnostics, 2018 - mdpi.com
Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and
these tumor cells may be accurately targeted for diagnosis by 68Ga-PSMA-positron …
these tumor cells may be accurately targeted for diagnosis by 68Ga-PSMA-positron …
Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients
MP Yadav, S Ballal, C Bal, RK Sahoo… - Clinical nuclear …, 2020 - journals.lww.com
Purpose The aim of this study was to evaluate the efficacy and safety of 177 Lu-PSMA-617
radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). Methods In …
radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). Methods In …
[HTML][HTML] Targeting PSMA revolutionizes the role of nuclear medicine in diagnosis and treatment of prostate cancer
Simple Summary Imaging plays a crucial role in the accurate staging of prostate cancer.
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer cells, and …
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer cells, and …